ELVN logo

ELVN
Enliven Therapeutics Inc

1,288
Mkt Cap
$2.51B
Volume
461,012.00
52W High
$48.53
52W Low
$14.79
PE Ratio
-21.69
ELVN Fundamentals
Price
$40.29
Prev Close
$41.20
Open
$41.09
50D MA
$37.36
Beta
1.47
Avg. Volume
1.02M
EPS (Annual)
-$1.83
P/B
5.21
Rev/Employee
$0.00
$410.41
Loading...
Loading...
News
all
press releases
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update PR Newswire...
PR Newswire·12h ago
News Placeholder
More News
News Placeholder
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell
Wall Street Zen downgraded shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·5d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Enliven Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·13d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High - Time to Buy?
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy...
MarketBeat·21d ago
News Placeholder
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 6,053,456...
MarketBeat·22d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2% - What's Next?
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 4.2% - What's Next...
MarketBeat·25d ago
News Placeholder
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to...
MarketBeat·26d ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High - Should You Buy?
Enliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week High - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Enliven Therapeutics in a note issued to investors on Thursday...
MarketBeat·1mo ago
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright
HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday...
MarketBeat·1mo ago
<
1
2
...
>

Latest ELVN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.